A study on the cognitive status of human papillomavirus among adult males in Tianjin based on the health belief model

Background:To understand the health beliefs and knowledge of human papillomavirus among adult males in Tianjin.Methods:An online questionnaire survey was conducted from 18 January 2023 to 6 March 2023 using snowball sampling method.Analyze the health belief scores and human papillomavirus(HPV)and HPV vaccine knowledge scores of adult males in Tianjin,and analyze their influencing factors.Results:A total of 388 adult males in Tianjin were surveyed,with an average total score of 3.23±0.04 for their health beliefs.Among them,the average scores for perceived severity,perceived susceptibility,perceived impairment,perceived benefit,and self-efficacy were 3.41±1.05,2.37±1.20,2.96±1.00,3.51±0.90,and 3.36±1.08,respectively.Multiple linear regression analyses showed education was a factor influencing health beliefs.The average total score of knowledge is 64.09±15.62,with 277 people scoring above 60,and a pass rate of 71.4%.Through multiple linear regression analysis,education level,emotional status,whether disease testing has been done,and whether family and friends have been diagnosed with HPV positive are the main influencing factors.Conclusion:The awareness rate of HPV among adult males in Tianjin is still acceptable,but there are still misconceptions.The overall level of health beliefs is moderate,and the perceived susceptibility level is low.It is necessary to strengthen health education on HPV related knowledge for males and improve their cognitive level.

治疗性HPV疫苗研究开发策略专家共识

人乳头瘤病毒(HPV)是双链DNA病毒,高危HPV感染易引发宫颈癌及癌前病变风险。近年来,已有超过400多种不同亚型的HPV被鉴定出,大多数HPV感染是无症状的,可以自行消退。免疫系统正常的女性,从感染高危HPV开始,通常需要15~20年才能发展为宫颈癌;但是对于免疫系统较弱的女性,如未经治疗的HIV感染女性(WLHIV),宫颈癌可能发展得更快(可能5~10年)。2006年,预防性HPV疫苗研发上市,但对已感染HPV或癌前病变患者无治疗效果。治疗性HPV疫苗的开发可为目前预防和治疗宫颈癌的方法提供重要的补充。与预防性HPV疫苗不同,治疗性疫苗旨在诱导特异性细胞免疫而非体液免疫(中和抗体),用于清除或治疗现有的HPV感染及其引起相关的癌前病变和侵袭性宫颈癌。因此,制定合理的治疗性HPV疫苗开发策略,不仅可以让治疗性HPV疫苗产品开发企业少走弯路,提高转化效率,而且可以使HPV感染及相关病变甚至癌变患者及早受益。本课题组织领域内专家学者,参考有关文件,结合HPV临床特点和发展背景,特别编撰了《治疗性HPV疫苗研究开发策略专家共识》,明确了适应范围、相关术语等,重点阐述了治疗性HPV疫苗临床开发方向、研究人群及特性和接种规划,旨在加快和推进治疗性HPV疫苗的研发,为社会研究开发治疗性HPV疫苗产品以及国家制定治疗性HPV疫苗相关政策提供借鉴和参考。

备孕女性HPV筛查及其疫苗接种状况调查

目的:调查备孕女性人乳头瘤病毒(HPV)感染情况并分析HPV疫苗接种影响因素。方法:收集2022年1月-2023年1月本院健康检查的211例备孕女性宫颈样本,采用聚合酶链式反应-反向点杂交法进行HPV感染亚型分型,通过问卷调查备孕女性HPV疫苗接种情况,分析影响备孕女性HPV疫苗接种影响因素。结果:备孕女性HPV感染率为22.7%,其中高危型HPV感染率为81.25%,主要HPV感染亚型为HPV52(18.8%)、HPV16(10.4%)。HPV单一型感染率为20.6%,多重感染率为14.6%。211例HPV疫苗接种率为14.7%,文化水平低、不知道HPV疫苗是影响备孕女性HPV疫苗接种的影响因素(P<0.05)。结论:本次调查的备孕女性HPV感染率为22.7%,以HPV52、HPV16为主要感染亚型;HPV疫苗接种率较低,应加强对备孕女性相关知识宣传,提高HPV疫苗接种率。

1658例生殖健康门诊男性HPV感染情况及基因型分布特征分析

目的了解生殖健康门诊男性的人乳头瘤病毒(human papillomavirus,HPV)感染情况和基因型分布特征,并比较各年龄组间是否存在差异。方法以2018—2022年在上海计生所医院门诊就诊的1658例男性为研究对象,采用PCR-反向点杂交法对23种HPV基因型进行检测。结果研究对象的HPV总感染率为22.50%。主要感染类型为单一感染(66.76%)。各年龄组HPV感染率的差异具有统计学意义(P<0.001),18~30岁、31~40岁、41~50岁和51岁及以上组HPV感染率分别为16.83%、22.87%、34.63%和29.35%。感染率居前5位的高危型HPV为HPV52(3.56%)、HPV16(3.26%)、HPV39(2.41%)、HPV51(2.17%)和HPV58(2.17%)。感染率最高的低危型HPV为HPV81(2.90%)。本研究中感染者的全部基因型能被HPV二价、四价、九价疫苗覆盖的比例分别为7.77%、12.33%和26.27%。结论本地区生殖健康门诊男性研究对象HPV感染类型以单一感染为主。高危基因型感染以HPV52、16、39、51和58最常见,低危基因型感染以HPV81最常见。41~50岁男性受检者的HPV感染率较高。

亚洲人群HPV疫苗免疫原性及安全性的Meta分析

目的评估人乳头状瘤病毒(HPV)疫苗在亚洲人群中接种后的免疫原性和安全性。方法本研究分别检索英文数据库(PubMed、Embase、Web of Science、Clinical Trails、Cochrane library)和中文数据库(中国知网、万方、维普),自建库至2022年4月,关于亚洲人群进行的HPV疫苗安全性和免疫原性临床试验文献。采用主题词与自由词灵活搭配检索并结合纳排标准筛选文献,对最终纳入文献进行质量评价并提取资料,应用Meta分析合并评估。结果最终纳入16篇随机对照试验(RCT)研究,累计研究对象25485人。Meta分析表明对于HPV疫苗免疫原性,HPV16型特异性血清转化率合并效应值RR为43.74(16.51~115.85),HPV18型特异性血清转化率合并效应值RR为45.72(8.78~238.13)。对于HPV疫苗安全性,二价与四价HPV疫苗接种局部不良事件风险试验组高于对照组,RR为1.52(1.34~1.73)和1.38(1.20~1.59)。二价HPV疫苗与四价HPV疫苗试验组发生全身性不良事件的风险也高于对照组,RR分别为1.21(1.11~1.32)和1.13(0.99~1.30)。结论接种亚洲人群HPV疫苗后血清抗体阳转率高于未接种者,提示接种HPV疫苗可以提高个体特异性抗体水平,接种HPV疫苗发生局部和全身性安全事件的风险均高于对照组,提示仍要高度重视HPV疫苗的安全性问题。

HPV16 E6、E7多表位DNA疫苗的构建及免疫效果评估

目的构建和评价HPV16 E6、E7多表位DNA疫苗诱导的特异性CTL细胞应答及其对肿瘤生长的干预作用,从而揭示其作为候选HPV治疗性疫苗的潜能。方法首先通过IEDB网站中的MHC I Processing Predictions和MHC I Binding Predictions方法,分别预测人类HLA-A^(*)02:01、HLA-A^(*)11:01、HLA-A^(*)24:02和C57BL/6小鼠H-2b的限制性CTL表位,然后根据评分以及ELISPOT实验筛选出二者共同呈递的CTL表位,并将其构建成多表位DNA疫苗(pVAX1-10P)。从预防性和治疗性二个方面研究pVAX1-10P对小鼠移植TC-1异位癌的免疫干预作用,流式细胞术检测特异性CTL应答。结果获得10条可被人与鼠MHC分子共呈递的CTL表位,ELISPOT结果表明这10条CTL表位均能诱导小鼠淋巴细胞产生特异性免疫应答;由此构建的多表位DNA疫苗pVAX1-10P无论在预防性实验还是治疗性实验中,均能诱导特异性的细胞免疫并抑制肿瘤的生长。结论构建的HPV16 E6、E7多表位DNA疫苗pVAX1-10P能够诱导特异性CTL应答,显著抑制肿瘤生长,有望作为候选HPV治疗性DNA疫苗。

Cervical Cancer Prevention Challenges and Barriers to Cervical Cancer Screening and HPV Vaccinations in Ukraine and Eastern Europe

Objectives: To identify the obstacles and issues that hinder effective cancer prevention efforts in Ukraine. The study aims to provide a comprehensive assessment of the barriers to cancer prevention, including both infrastructure and behavioral factors, and identify potential solutions to address these challenges. Study Design: Comprehensive literature review. Methods: The following databases were searched: National Center for Biotechnology Information (NCBI) and PubMed (U.S. National Library of Medicine at the National Institutes of Health). The keywords used in the search included “Cervical Cancer”, “Human Papillomavirus Vaccination (HPV)”, “Ukraine”, “Eastern Europe”, “Healthcare Infrastructure in Disasters”, “Cervical Cancer Prevention”, “Pap Smear”, and “HPV Testing”. Results: A total of 3500 articles were screened. A total of 65 articles met the inclusion criteria. Limited public awareness and limited access to vaccination and screening, combined with inadequate treatment facilities lead to higher rates of cervical cancer. The COVID pandemic, war with Russia, and the Chernobyl disaster are significant factors for the low level of vaccination in Ukraine. Conclusion: The prevention and treatment of cervical cancer in Ukraine face significant challenges due to the inadequate HPV vaccination rates and screening by cytology. Efforts to improve funding and increase education of both the population and health care providers are necessary to increase interventions such as HPV vaccination, cervical cytology, and HPV testing to reduce cervical cancer rates in Ukraine.

HPV-16 E6E7抗原表位嵌合体DNA疫苗黏膜免疫抑制宫颈癌的效果研究

目的 评价泛素及热休克蛋白70(HSP 70)C融合人乳头瘤病毒(HPV)16型E6E7表位嵌合体DNA疫苗鼻内黏膜免疫对宫颈癌移植瘤的预防和治疗效果。方法 建立TC-1小鼠肿瘤模型,以壳聚糖为发送载体,通过滴鼻免疫给药免疫C57BL/6小鼠。MTT法和淋巴毒性T细胞(CTL)反应检测小鼠脾脏T淋巴细胞增殖、流式细胞术检测细胞因子表达水平、肿瘤生长曲线和荷瘤小鼠存活时间评价壳聚糖包裹的HPV-16 E6E7嵌合体DNA疫苗鼻内黏膜免疫后对HPV-16型相关宫颈癌移植瘤的预防和治疗效果。结果 与对照组pcD-UH相比,实验组pcD-UE和pcD-UEH均具有显著的CTL反应,延缓HPV-16型相关宫颈癌移植瘤生长,但对已生成肿瘤无影响。鼻内黏膜途径发送壳聚糖包裹HPV-16 E6E7抗原表位嵌合体DNA疫苗仅能产生较弱的细胞免疫应答。结论 HPV-16 E6E7抗原表位嵌合体DNA疫苗通过鼻腔免疫,具有一定的肿瘤治疗和显著的肿瘤预防效果,为新型HPV疫苗的研制奠定了基础。

口腔HPV感染的研究现状

流行病学证据表明口腔是人乳头瘤病毒(human papillomaviruses,HPV)的储存库,水平传播和垂直传播等多种途径促进了口腔HPV感染的流行。低危型HPV感染可能导致口腔黏膜良性病变,而高危型HPV的持续感染是诱发头颈部鳞状细胞癌的重要危险因素。目前,我国关于口腔HPV感染的研究工作并不深入,国人对相关知识的认知不足,这不利于相关疾病防治工作的开展。在此背景下,本文对口腔HPV感染的研究现状进行综述,以期为我国口腔HPV感染的防治工作提供参考。

Distribution of High-Risk Human Papillomavirus Genotypes among Women with Colposcopic Diagnosis of Cervical Intraepithelial Neoplasia in Bangladesh

Background: The incidence of cervical cancer is high in Bangladesh and there is a high prevalence of preinvasive lower genital tract disease among women of reproductive age. Persistent high-risk Human Papilloma Virus (HPV) infection is the main underlying cause of cervical cancer and its precursor, cervical intraepithelial neoplasia (CIN). Objective: The aim of the study was to identify the subtypes of high-risk HPV infection among women with the colposcopic diagnosis of cervical intraepithelial neoplasia in Bangladesh. Methods: This cross-sectional observational study was conducted in the colposcopy clinic of Dhaka Medical College Hospital over a six-month period. A total of 100 participants were enrolled. Married women, between 30 - 60 years of age with colposcopically diagnosed cervical intra epithelial neoplasia were enrolled. Women with chronic illness, pregnancy, and women unable to consent were excluded from this study. After counselling, colposcopically directed punch biopsies were taken from each CIN case concurrently with high-risk HPV testing by polymerase chain reaction (PCR). Results: The mean age of the patients was 38.69 (SD ±7.76) years. CIN 1 was diagnosed in 57% of participants, while 24% had CIN II and 19% had CIN III lesions. High-risk HPV was present in 52 patients. HPV 16 was the most common identified in 28 (53.84%) and HPV 18 was the second most common with 20 (38.46%) either singly or in combination with other high-risk subtypes. The other HPV strains, HPV 31, 33, 35, 52, 56 and 58, were also detected either as mono or co-infections. Out of the 52 HPV positive cases, 29 (55.8%) had mono infection and 23 (44.2%) had co-infection with several subtypes. The highest incidence (50%) of oncogenic HPV infections was present among women aged 35 - 45 years. Risk factors associated with HPV positive cases were high parity (P 0.05), early age at marriage (P = 0.754) and early age of first child. Conclusion: This study identified a high prevalence of HPV 16 and 18 genotypes. HPV vaccination with the current 9-valent HPV vaccine, which contains HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. Will be an effective public health measure to eradicate cervical cancer in Bangladesh.

经阴道分离膀胱直肠间隙的宫颈LEEP术后HPV转阴情况及生育能力分析

目的探讨子宫颈高级别鳞状上皮内病变(high-grade cervical intraepithelial neoplasia,HSIL)患者行经阴道分离膀胱直肠间隙的宫颈环形电切术(loop electrosurgical excision procedure,LEEP)后人乳头状瘤病毒(human papillomavirus,HPV)转阴情况及生育力。方法收集2019年1—12月在复旦大学附属妇产科医院行经阴道分离膀胱直肠间隙的宫颈LEEP术患者53例,术后行子宫颈脱落细胞学检查、HPV检测和阴道镜下子宫颈活检,随访时间分别为6、12和24个月。分析患者术前HPV感染分布及保育成功率,经阴道分离膀胱直肠间隙的宫颈LEEP术后HPV转阴情况,术后切缘阳性和病理类型分布,HPV感染类型对术后切缘阳性的影响及患者术后生育情况。结果53例患者中,94.3%(50/53)存在HPV感染,其中75.5%(40/53)为HPV16/18型感染者,69.8%(37/53)为HPV单一亚型感染,高于混合感染22.7%(12/53);71.7%(38/53)前次LEEP术后切缘阳性,28.3%(15/53)HSIL复发;56.6%(30/53)术后病理HSIL,28.3%(15/53)未发现病理性改变;75.5%(40/53)术后切缘阴性(即保育成功),其中95%(38/40)HPV转阴。比较HPV16/18感染(P=0.196)和HPV感染类型(P=1.000)对术后切缘阳性的影响,差异无统计学意义。5例保育成功的患者在术后完成生育(12.5%,5/40),其中顺产1例,剖宫产4例。5例均为足月分娩,3例行宫颈环扎术,2例患者未行宫颈环扎。结论子宫颈HSIL患者行经阴道分离膀胱直肠间隙的宫颈LEEP术后保育成功率高,术后HPV转阴率高。

HPV感染的慢病管理

目前HPV的感染在全球人群中普遍存在,并且HPV感染人体后很难被彻底清除,因此由HPV感染所诱发的多种慢性疾病如病毒疣、宫颈上皮内瘤变、呼吸道乳头状瘤等往往存在着很高的复发率,给患者乃至社会均带来了沉重负担。因此,需要对HPV感染所诱发的慢性疾病进行科学规范的管理,进而降低HPV感染率与疾病复发率、缩短病程,从而有效促进HPV的防治工作。本文就HPV感染的慢病管理的必要性、具体方法及其意义进行综述。

宫颈LEEP术后接种HPV疫苗对宫颈上皮内瘤变患者预后的影响研究

目的:探讨宫颈环形电切除术(LEEP)术后接种人乳头瘤病毒(HPV)疫苗对宫颈上皮内瘤变(CIN)患者预后的影响。方法:在江西省信丰县人民医院选取2019年6月—2021年6月收治CIN患者76例,采用Excel表格建立随机数字表法分组,38例观察组与38例对照组,两组均接受LEEP术治疗,观察组术后按0/2/6程序接种二价HPV疫苗,对照组术后不接种HPV疫苗。对比两组患者HPV阳性率变化、术后CIN复发情况及生活质量。结果:两组术后6个月及接种完成后3个月、6个月、12个月HPV阳性率对比,观察组均比对照组低(P<0.05)。两组术后12个月、15个月及18个月CIN复发率对比,观察组均比对照组低(P<0.05)。术后两组生活质量量表(SF-36)得分与术前对比均有所升高,且观察组术后得分升高幅度更显著(P<0.05)。结论:CIN患者LEEP术后接种二价HPV疫苗,能够降低术后HPV阳性率及CIN复发率,提升生活质量,为患者带来福音,值得推广。

Reid阴道镜评分、HPV E6/E7 mRNA表达量在宫颈癌中的临床应用价值研究

目的研究Reid阴道镜评分(以下简称Reid评分)、高危型人乳头瘤病毒(HR-HPV)mRNA表达量与宫颈癌国际妇产科联盟(FIGO)分期、血清常规肿瘤标志物水平的相关性及对宫颈癌术后淋巴结转移的预测价值。方法选取2021年3月至2022年5月在菏泽市立医院就诊的100例宫颈癌患者作为宫颈癌组,另选同期诊治的50例低级别鳞状上皮内病变(LSIL)患者作为LSIL组,50例高级别鳞状上皮内病变(HSIL)患者作为HSIL组。比较3组Reid评分、HPV E6/E7 mRNA表达量及血清常规肿瘤标志物[糖类抗原125(CA125)、癌胚抗原(CEA)]水平;分析宫颈癌组Reid评分、HPV E6/E7 mRNA表达量与血清常规肿瘤标志物水平及宫颈癌FIGO分期的相关性;根据宫颈癌组患者术后随访结果分为术后有淋巴结转移和无淋巴结转移,比较有无淋巴结转移患者Reid评分、HPV E6/E7 mRNA表达量及血清CA125、CEA水平,分析Reid评分、HPV E6/E7 mRNA表达量对宫颈癌术后淋巴结转移的预测价值。结果宫颈癌组Reid评分、HPV E6/E7 mRNA表达量及血清CA125、CEA水平均高于HSIL组、LSIL组(P<0.05);HSIL组Reid评分、HPV E6/E7 mRNA表达量及血清CA125、CEA水平均高于LSIL组(P<0.05)。宫颈癌患者Reid评分、HPV E6/E7 mRNA表达量与血清CA125、CEA水平均呈正相关(r=0.405~0.705,P<0.05)。Reid评分、HPV E6/E7 mRNA表达量与宫颈癌FIGO分期呈正相关(r=0.415、0.501,P<0.05)。宫颈癌组术后淋巴结转移患者的Reid评分、HPV E6/E7 mRNA表达量及血清CA125、CEA水平均高于无淋巴结转移的患者(P<0.001)。Reid评分、HPV E6/E7 mRNA表达量、CA125、CEA预测宫颈癌术后淋巴结转移的曲线下面积(AUC)分别为0.756(95%CI:0.657~0.838)、0.760(95%CI:0.662~0.841)、0.803(95%CI:0.710~0.877)、0.768(95%CI:0.670~0.848)。将CA125、CEA联合检测作为常规预测方案,Reid评分、HPV E6/E7 mRNA表达量、CA125、CEA联合检测作为新预测方案,常规预测方案预测宫颈癌术后淋巴结转移的曲线下面积(AUC)为0.826(95%CI:0.724~0.889),新预测方案预测宫颈癌术后淋巴结转移的AUC为0.955(95%CI:0.892~0.987),新预测方案预测的AUC明显大于常规预测方案(Z=1.981,P=0.045)。与常规预测方案比较,新预测方案的净重新分类指数为0.021(95%CI:0.015~0.039)、综合判别改善指数为0.046(95%CI:0.033~0.069),均P<0.05。结论Reid评分、HPV E6/E7 mRNA表达量与宫颈癌FIGO分期及血清CEA、CA125水平相关,且在预测宫颈癌术后淋巴结转移方面具有一定价值。

Awareness and knowledge of human papillomavirus vaccination and their influential factors among Chinese women: a systematic review

Objectives: To systematically review the knowledge attitudes and the influential factors on human papillomavirus(HPV) vaccination among Chinese women.Methods: Published studies on knowledge and attitudes of HPV vaccination for preventing cervical cancer among Chinese female population were retrieved using the major Chinese and English databases. Meanwhile, handwork retrieval was also conducted and the references including in the literature were retrieved. The quality of the literature was rigorously evaluated and extracted independently by two researchers and the data were analyzed and described by review manager 5.3(RevMan5.3) software.Results: In all, 19 articles including 8 articles in Chinese and 11 in English were chosen. A total of 30,176 participants were included and the sample size ranged from 64 to 6,024. The overall awareness of HPV and HPV vaccine among Chinese women was at a low level. Chinese women generally showed poor knowledge about HPV and HPV vaccine. Acceptance of HPV vaccination among Chinese women was at a high level. Vaccination intentions were influenced by the theory of planned behavior(TPB) and measured by attitudes subjective norms and perceived behavioral control.Conclusions: The health authorities may evaluate and develop TPB-based interventions to increase HPV vaccination intentions of Chinese women. HPV vaccination programs should focus on carrying out multi-level and targeted health education and developing effective public health strategies after balancing the cost and benefit of HPV vaccine program. Medical staff should play the positive role in promoting the use of HPV vaccines in China. Integration of policy and community perspectives and multi-level interventions are essential to maximize the public health benefits of HPV vaccination.

SEARCH FOR HERPES SIMPLEX VIRUS TYPE2（HSV－2）AND HUMAN PAPILLOMAVIRUS（HPV）IN THE NORMAL AND ABNORMAL CERVICAL SAMPLES

The specimens of 111 cervical carcinomas. 68 chronic cervicitis and 43 normal cervical exfoliated epithelial cells were examined for the presence of HSV2 DNA sequences with DNA hybridization using HSV2 BgL Ⅱ N fragment probe labelled by 32PdCTP. The result showed that the infection rates of HSV2 in the samples of cervical cancer.chronic cervicitis and normal epithelial cells were 1 4. 41 %(16/111). 27.94%( 19/68) and 25.58% ( 11/43),respectively. It was implied that early stages carcinogenesis of cervical epithelial cells might be correlated with the HSV2 infection.Sixteen HSV 2 positive samples of cervical carcinomas were also examined for the presence of the sequences homologous to human papillomavirus (HPV) type 6B/11. 16 and 18 DNA using dot blot hybridization (Tm17℃). The result indicated that 13 out of 16 were HPV 16 DNA hybridization positive accounting for 81. 2% of all HSV-2 positive samples and none of them were positive for HPV type 6B/11 and 18. The result indicated that double infection of HSV 2 and HPV16 in the same cervical carcinoma tissues may provide a strong evidence of the viral synergistic interaction in the induction of female cervical

某三甲医院周边区域妇女宫颈HPV感染状况及相关风险因素

目的探讨某三甲医院周边区域妇女宫颈HPV感染状况及相关风险因素。方法选取常住在武警特色医学中心周边10 km以内,并于2020-01至2023-07在该中心妇科门诊自然就诊的妇女为研究对象,通过问卷调查、宫颈上皮脱落细胞HPV分型检测,对HPV感染状况及与感染相关因素进行统计学分析。结果该中心周边区域自然就诊的女性共入选5967名,宫颈HPV感染1122例,感染率为18.80%,其中单一感染占78.61%(882/1122),多重感染占21.39%(240/1122)。多重感染包括2~5种HPV亚型的混合感染,其中双重感染率2.77%(165/5967),三重感染率1.06%(63/5967),四重感染率0.15%(9/5967),五重感染率0.05%(3/5967)。HPV高危型单一感染率12.42%(741/5967),HPV低危型单一感染率2.36%(141/5967)。感染率由高到低排名前5位的依次为52型(3.17%)、16型(2.92%)、53型(2.66%)、58型(1.66%)、56型(1.46%)。既往性伙伴个数(OR 1.559,95%CI 1.409~1.724)和初次性生活年龄(OR 0.820,95%CI 0.707~0.952)是HPV感染的相关风险因素。结论该区域内自然就诊的妇女感染HPV亚型有自身特点,以单一感染为主,HPV型别以52型、16型、53型、58型和56型为主,既往性伙伴人数和初次性生活年龄是HPV感染的相关风险因素。

A Case with XXXX Syndrome Who Was Incidentally Diagnosed during Examination for Suspected Post-Human Papillomavirus Vaccination Syndrome

A 19-year-old Japanese woman was referred to us with the complaints of arthralgia and meralgia following human papillomavirus (HPV) vaccination. She received HPV vaccination at the age of 15 years and three years later, she developed intermittent arthralgia, meralgia, and numbness in limbs. There were no orthostatic dysregulation symptoms. She had hypertelorism, and brachydactyly in both the hands, and revealed mild cubitus varus deformity with lateral instability. X-ray examination disclosed hypoplasia of the humeral capitellum and trochlea in elbow joints. G-banded chromosomes were shown to be composed of 48, XXXX. She was, therefore, diagnosed with XXXX syndrome, which explained the reason for her limb symptoms. Although some girls with HPV vaccination complain of various symptoms including limb pain and numbness, exact underlying cause of these symptoms needs to be ascertained carefully for reaching a final diagnosis.

福建省泉州市大学生HPV疫苗接种情况与认知调查

目的:分析福建省泉州市大学生对人乳头瘤病毒(Human Papilloma Virus,HPV)疫苗的接种意愿、接种情况及认知状况,为HPV疫苗的接种与推广提供参考依据。方法:于2023年2月-2024年2月,选取泉州市500名在校大学生进行问卷调查,并分析相关数据。结果:泉州市愿意接种HPV疫苗的大学生占比为47.6%,其中女生96.2%,男生3.8%,且在年龄分布、专业背景以及是否有过性生活等方面的差异有统计学意义(p <0.05)。70.0%的大学生表示听过HPV疫苗或HPV病毒,且接种率达22.2%;92.4%的大学生认为接种HPV疫苗后完全受益,但仍有76.4%的大学生担心HPV疫苗安全性。结论:泉州市大学生对HPV疫苗接种的认知度以及疫苗接种率偏低,建议相关部门或学校应加强大学生健康教育,降低疫苗价格,提高学生对HPV的认知水平。

国内女性HPV感染及预防性疫苗接种的研究进展

目前,人乳头瘤病毒(HPV)感染在全球范围内仍然是一种常见的性传播疾病,对女性健康带来了重大威胁。宫颈癌是女性常见的恶性肿瘤之一,其主要致病原因是高危型别的HPV的持续感染。近年来,随着人们对宫颈癌研究的深入,国内对女性HPV感染情况的研究日趋重视。同时,HPV疫苗作为一种预防HPV感染的有效手段也引起了广泛关注。本文对近年来高危型HPV感染在宫颈癌中作用机制的研究进展、国内女性感染情况,以及HPV预防性疫苗接种情况、存在的问题和未来方向作一综述。